<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Jensen JT</submitter><funding>NICHD NIH HHS</funding><funding>NICHD</funding><funding>NIH Library</funding><funding>NIH HHS</funding><pagination>110475</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11297684</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>137</volume><pubmed_abstract>&lt;h4>Objectives&lt;/h4>To evaluate ovulation risk among women enrolling in an emergency contraception (EC) study by measuring contraceptive steroids and ovarian hormones.&lt;h4>Study design&lt;/h4>We used standard chemiluminescent assays to evaluate endogenous hormones (estradiol, progesterone, follicle stimulating hormone, luteinizing hormone) and liquid chromatography-tandem triple quadrupole mass spectrometry to simultaneously analyze concentrations of ethinylestradiol, dienogest, norelgestromin (NGMN), norethindrone (NET), gestodene, levonorgestrel (LNG), etonogestrel (ENG), segesterone acetate, medroxyprogesterone acetate (MPA), and drospirenone in serum samples obtained at the time of enrollment in a recent study comparing oral ulipristal acetate and LNG EC in women with weight ≥80 kg reportin</pubmed_abstract><journal>Contraception</journal><pubmed_title>Use of serum evaluation of contraceptive and ovarian hormones to assess reduced risk of pregnancy among women presenting for emergency contraception in a multicenter clinical trial.</pubmed_title><pmcid>PMC11297684</pmcid><funding_grant_id>HHSN275200403378I</funding_grant_id><funding_grant_id>P51 OD011092</funding_grant_id><pubmed_authors>Edelman A</pubmed_authors><pubmed_authors>Schreiber CA</pubmed_authors><pubmed_authors>Thomas M</pubmed_authors><pubmed_authors>Westhoff CL</pubmed_authors><pubmed_authors>Archer DF</pubmed_authors><pubmed_authors>Brown J</pubmed_authors><pubmed_authors>Jensen JT</pubmed_authors><pubmed_authors>Teal S</pubmed_authors><pubmed_authors>Blithe DL</pubmed_authors></additional><is_claimable>false</is_claimable><name>Use of serum evaluation of contraceptive and ovarian hormones to assess reduced risk of pregnancy among women presenting for emergency contraception in a multicenter clinical trial.</name><description>&lt;h4>Objectives&lt;/h4>To evaluate ovulation risk among women enrolling in an emergency contraception (EC) study by measuring contraceptive steroids and ovarian hormones.&lt;h4>Study design&lt;/h4>We used standard chemiluminescent assays to evaluate endogenous hormones (estradiol, progesterone, follicle stimulating hormone, luteinizing hormone) and liquid chromatography-tandem triple quadrupole mass spectrometry to simultaneously analyze concentrations of ethinylestradiol, dienogest, norelgestromin (NGMN), norethindrone (NET), gestodene, levonorgestrel (LNG), etonogestrel (ENG), segesterone acetate, medroxyprogesterone acetate (MPA), and drospirenone in serum samples obtained at the time of enrollment in a recent study comparing oral ulipristal acetate and LNG EC in women with weight ≥80 kg reportin</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Sep</publication><modification>2026-05-29T07:00:07.236Z</modification><creation>2026-04-08T03:51:42.542Z</creation></dates><accession>S-EPMC11297684</accession><cross_references><pubmed>38670302</pubmed><doi>10.1016/j.contraception.2024.110475</doi></cross_references></HashMap>